tbuckley/cabot-search huggingface dataset:
Abstract 15187: Shear Stress-regulated Mir-27b Controls Pericyte Recruitment <i>in vitro</i> and <i>in vivo</i> and Contributes to Vessel Maturation
Authors: Shemsi Demolli, Anuradha Doddaballapur, Konstantin Stark, Reinier A Boon, Ankathrin Eckart, Thomas Korff, Markus Hecker, Yosif Manavski, Tina Lucas, Steffen Massberg, Kavi Devraj, Stefan Liebner, David Kaluza, Stefanie Dimmeler
Journal: Circulation (2015)

Vessel maturation involves recruitment of mural cells. Laminar shear stress is a major trigger for vessel maturation. However, the molecular mechanisms by which shear stress affects recruitment of pericytes are unclear. MicroRNAs are small non-coding RNAs, which post-transcriptionally control gene expression. Since shear stress regulates various miRs, we hypothesize that flow-induced miRs inhibit repulsive cues and facilitate mural cell coverage. Laminar shear stress for 72h induces the up-regulation of miR-27b (2.8±0.24-fold vs static, p&lt;0.05) in cultured endothelial cells (ECs) and in mouse femoral artery segments that were exposed to physiological shear stress ex vivo (1.5±0.14-fold vs no flow, p&lt;0.05). Predicted targets for miR-27b include members of the semaphorin (SEMA) family (known to regulate repulsive signaling) and angiopoietin-2 (Ang2), which causes vessel destabilization. MiR-27b overexpression reduces SEMA6A (63.5±13.5%), SEMA6D (58±26%), and Ang2 (51.5±11%) expression. To determine whether miR-27b controls pericyte recruitment, we tested the effect of endothelial miR-27b on adhesion of pericytes. Overexpression of miR-27b increased the adhesion of pericytes (p&lt;0.05) and inhibition of miR-27b reduced pericyte adhesion in vitro (p&lt;0.05). In an in vitro matrigel assay, overexpression of miR-27b increased pericyte coverage of endothelial cell tubes (155±45%, p&lt;0.05), whereas inhibition of miR-27b reduced pericyte coverage (81±15%). In addition, overexpression of miR-27b in vitro increases barrier function (p&lt;0.05) in endothelial cell-pericyte co-culture assays whereas inhibition of miR-27b decreases barrier function (p&lt;0.05). Silencing of SEMA6A and SEMA6D rescued the reduced pericyte adhesion that is caused by miR-27 inhibition (p&lt;0.05). Furthermore, inhibition of SEMA6D increases barrier function. In vivo inhibition of miR-27a/b significantly increased edema (p&lt;0.05) in the uterus which was associated with a significantly reduced pericyte coverage of the vessels (p&lt;0.05). Taken together, our data demonstrate that shear stress regulate miR-27b, which targets Ang2 and semaphorins, thereby controlling pericyte adhesion and coverage in vitro and in vivo.
COMPUTERS AND THE PRACTICE OF MEDICINE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"ERROR OF BASING SERUM DIAGNOSIS OF SYPHILIS ON THE KAHN REACTION ALONE"
Authors: Sigmund S. Greenbaum
Journal: JAMA (1927)

<h3>To the Editor:</h3> —A communication from Dr. A. V. Greaves (The Journal, March 19, p. 945) "serves as an admirable peg on which to hang" a reiteration of certain remarks made in my article entitled "Error of Basing Serum Diagnosis of Syphilis on the Kahn Reaction Alone" (The Journal, April 24, 1926, p. 1273). Almost a year has elapsed since the publication of the paper, and I am more than ever convinced of the fitness of the title and of the conclusions it contains. I have always felt that the value of a biologic test must be based on clinical rather than laboratory grounds. My article was therefore based on serologic reports (Kolmer and Kahn tests) to a large syphilitic service by one of the most able and careful of serologists, who knew nothing concerning the patients whose serums were tested. The fifty negative Kahn and Kolmer reactions constitute but
Schizophrenia in the Kenya Native
Journal: BMJ (1936)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Schizophrenia in the Kenya Native Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Erratum
Authors: Chester Street, Belgrave Square, William Brinton, Bloomsbury Street; -Frere, May Fair, ; Stephen, Jennings Goodfellow, Clement Hue, Alex Stewart, Grosvenor Street, Grosvenor Square, ; Goodman, Henry Collins, Henry Smyth Locock, Lee Park, Blackheath Henry, Thomas Spratt, Walter Arthur, Liverpool Henry, Scholfield Johnson, Francis Hunt
Journal: BMJ (1850)
Cerebral Apoplexy
Authors: George Margolis
Journal: JAMA (1962)

This slim volume is of particular value because it represents the first detailed presentation of the author's views on this subject in the English language. A major thesis is that there are common features in the pathogenesis of the three recognized etiologic types of strokes and that neurogenic circulatory disturbances are important in the development of these processes. The author presents an excellent historical background and makes free use of descriptive and photographic material which appeared in his older works. It is predictable that many readers will disagree with the conclusions expressed here. The amount of historical and descriptive information in this book and the comprehensive approach of the author to the problem make this text a valuable source of information.
The Skin
Authors: Hugh A. Sampson
Journal: Allergy (1995)

•Ingested food antigens rapidly cross the gastrointestinal barrier and reach pro‐inflammatory cells in the skin. •Food allergy provokes urticaria/angioedema by classical, Type I, IgE‐mediated hypersensitivity. •Food‐induced atopic dermatitis is the result of non‐classical, IgE‐directed hypersensitivity involving resident mast cells, Langerhans cells, CD4+ TH 2 lymphocytes and monocytes. •A form of gluten sensitivity provokes a characteristic eczematous‐like rash and enteropathy (Dermatitis herpetiformis).
Oral clonidine loading in hypertensive urgencies
Authors: R. J. Anderson
Journal: JAMA (1981)

The response to oral clonidine hydrochloride loading in 36 severely hypertensive patients is presented. Each patient initially received 0.2 mg of clonidine hydrochloride, followed by 0.1 mg each hour until a dose of 0.7 mg had been given, or the diastolic blood pressure (BP) reached a predetermined goal (110 mm Hg or total fall of at least 20 mm Hg). Only two patients (6%) failed to reach this goal. Supine BP in the group fell from 212±22 (SD)/139±11 (SD) mm Hg to 151±21 (SD)/103±11 (SD) mm Hg at six hours. The average dose of clonidine required was 0.45 mg and control was maximized at five hours. The response to oral clonidine loading in the individual patient was not predictive of the eventual dose of clonidine necessary to achieve acceptable BP control at two weeks. Oral clonidine loading is safe and effective in the management of "hypertensive urgencies" and offers several advantages over parenteral antihypertensive agents in this clinical situation. (<i>JAMA</i>1981;246:848-850)
A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.
Authors: John D. Shaughnessy, Fenghuang Zhan, Bart Burington, Yongsheng Huang, Ichiro Hanamura, James P. Stewart, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, John Crowley, Bart Barlogie
Journal: Blood (2006)
Erratum to: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
Authors: Jan J. De Waele, J. Lipman, M. Akova, M. Bassetti, G. Dimopoulos, M. Kaukonen, D. Koulenti, C. Martin, P. Montravers, J. Rello, A. Rhodes, A. A. Udy, T. Starr, S. C. Wallis, J. A. Roberts
Journal: Intensive Care Medicine (2015)
Revised Plan for Celebration of National Cancer Institute Semicentennial
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Revised Plan for Celebration of National Cancer Institute Semicentennial Get access JNCI: Journal of the National Cancer Institute, Volume 78, Issue 4, April 1987, Page 785, https://doi.org/10.1093/jnci/78.4.785 Published: 01 April 1987
Abstract 430: Inhibition of Aneurysm Development by Intra-peritoneal Application of Ribbon-type Decoy Oligodeoxynucleotide against Nuclear Factor-κB and Ets in a Rat Model
Authors: Takashi Miyake, Motokuni Aoki, Yoshikazu Fujiwara, Hirofumi Makino, Ryuichi Morishita
Journal: Circulation (2008)

As elective surgical or endovascular repair is not effective to improve survival of small abdominal aortic aneurysm (AAA), the development of a novel therapeutic approach for treating small AAA is awaited. We have previously reported the regressive effect of chimeric decoy oligodeoxynucleotides (ODN) against NFκB and ets in an experimental AAA model. However, local application of conventional phosphorothioated chimeric decoy ODN (PC-ODN) was necessary due to easily degradation. Therefore, we developed a novel chimeric decoy ODN with a ribbon-shaped circular structure (RC-ODN) to stabilize decoy ODN against nucleases. Transfection of RC-ODN inhibited MMP-2 expression in VSMC, but not MMP-9 expression. In contrast, in cultured THP-1 cells, MMP-9 expression was suppressed by RC-ODN, whereas MMP-2 expression was not altered. Interestingly, these inhibitory effects of RC-ODN were more potent than that of PC-ODN (n=8, P&lt;0.05). Next, intra-peritoneal application of RC-ODN was performed in an elastase-induced rat AAA model. One week after injection, FITC-labeled RC-ODN were detected in migrating macrophages into aneurysm wall. In addition, both NFκB and ets activity were suppressed by RC-ODN. Four weeks after treatment, RC-ODN treatment inhibited the aortic dilatation as compared to control or scrambled decoy ODN transfer (n=6, P&lt;0.05), while PC-ODN treatment failed to prevent aneurysm formation. Interestingly, a significant preservation of elastic fibers was observed with RC-ODN treatment, accompanied by a reduction of expression of MMP-9, MMP-12, cathepsin B and cathepsin K (P&lt;0.05), while the recruitment of macrophages was not inhibited. Finally, to consider the clinical application, we investigated the effect of intravenous injection of RC-ODN. Four weeks after infusion of angiotensin II in apolipoprotein E-deficient mice, intravenous injection of RC-ODN (1 mg/Kg) was performed 3 times per week. RC-ODN treatment showed a tendency to decrease the size of AAA, but not significant. In conclusion, the present study provided a novel strategy to treat AAA using intra-peritoneal application of RC-ODN in a rat model. Further development of this strategy would be useful to treat human AAA, as a minimally invasive molecular therapy.
Respiratory atopic disease
Authors: K. P. Mathews
Journal: JAMA (1982)

THE COMMON allergic respiratory diseases are discussed first in this primer because of their clinical importance. Although both rhinitis and asthma can occur without a recognized allergic mechanism, IgE-mediated inflammation is an important consideration in these diseases and is a critical consideration in the differential diagnosis of both entities. It is estimated that 35 million Americans have asthma and other allergic diseases. That this group of diseases is an important health burden can be seen from figures compiled by the National Center for Health Statistics. For example, approximately 9% of all patients seeking medical care at a physician's office do so for one of the common allergic diseases. Furthermore, among chronic illnesses of childhood, asthma is the most frequent cause of school absenteeism. Of the 35 million Americans with allergic disease, an estimated 8.9 million suffer from asthma with or without hay fever, 14.7 million have hay fever alone, and
The Cervical Spine
Authors: Leonard F. Peltier
Journal: JAMA (1989)

When the original edition of this work was published in 1983 under the sponsorship of the Cervical Spine Research Society, the chairman of the editorial subcommittee was Robert W. Bailey. This second edition is dedicated to his memory. The success of the first edition can be attributed to the quality and depth of the material presented and the need for a second edition is evident from the amount of new material incorporated in it. The size of the work has increased from 544 pages to 881 pages. There are excellent new sections on three-dimensional computed tomography and magnetic resonance imaging of the cervical spine and spinal cord, by Christopher G. Ullrich of Johns Hopkins. The French surgeons, Raymond Roy-Camille, Gerard Saillant, and Christian Mazel have contributed an important new section on the internal fixation of unstable fractures and dislocations. There is a new section on athletic injuries of the cervical
Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.
Authors: Gopi Kesaria Prithviraj, Kathryn Anissa Baksh, William J. Fulp, Kenneth L. Meredith, Sarah E. Hoffe, Ravi Shridhar, Khaldoun Almhanna
Journal: Journal of Clinical Oncology (2014)

e15070 Background: Survival in patients with metastatic esophageal and gastric cancer is dismal. No standard treatment has been established. Carboplatin/paclitaxel is active in both advanced gastric and esophageal cancer. Here we present the data of our single center retrospective analysis. Methods: Between 1998-2013, a total of 134 patients with metastatic esophageal and gastric adenocarcinoma treated with carbo/taxol (carboplatin predominantly AUC 5 and paclitaxel predominantly 175 mg/m2) every 3 weeks, as first-line therapy were identified. Baseline characteristics, response to therapy, toxicities, and survival in this patient population were evaluated. Overall survival was defined as date from biopsy to death or last follow-up and progression-free survival was defined at time from cycle 1 to death, progression, or last follow-up. Kaplan-Meier curves were fit to estimate overall and progression-free survival. Results: Of the 134 patients evaluated, the median age at diagnosis was 65 years. Overall response rate (ORR) was 62.6% (complete response (CR)- 11%, partial response (PR)- 28%, stable disease (SD)-33%). Median overall survival from date of initial diagnosis was 1.29 years (95% confidence interval [CI] 1.06-1.5). Median progression-free survival from date of initiation of carboplatin and paclitaxel was 0.44 years (95% CI 0.34-0.5). Grade III toxicity occurred in 18.7% of patients. The most common grade III toxicity was neuropathy, present in 3.7% of total study population. Conclusions: In patients with metastatic or unresectable esophageal or gastric cancer, the combination of carboplatin and paclitaxel is well tolerated with comparable overall survival and progression-free survival to existing regimens in this population.
Recertification
Authors: Robert S. Crausman
Journal: Annals of Internal Medicine (2002)

Letters17 December 2002RecertificationRobert S. Crausman, MDRobert S. Crausman, MDBrown University Medical School; Pawtucket, RI 02860Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-12-200212170-00038 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:At the 2002 annual meeting of the American College of Physicians–American Society of Internal Medicine, I was pleased to learn that the College will be redoubling its efforts to work with the American Board of Internal Medicine to develop an improved recertification system that will be meaningful for practicing internists and ensure lifelong professional development. As one of the many Fellows of the College who have a time-limited certificate, and one who recently recertified under the current less-than-ideal system, I believe that periodic recertification is here to stay. I also think that overall this is a good ... Author, Article, and Disclosure InformationAuthors: Robert S. Crausman, MDAffiliations: Brown University Medical School; Pawtucket, RI 02860 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe American Board of Orthodontics: Diplomate recertification 17 December 2002Volume 137, Issue 12Page: 1014KeywordsForecasting ePublished: 17 December 2002 Issue Published: 17 December 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Direct infarct intervention in women: Is there a gender difference in clinical outcomes? Ambika Bhaskaran, Robert M. Siegel, Barbara Barker, Warren Breisblatt, Charles Jost, Warren Zeitlin, Stephen Cantor, Sheryn Shimamoto, Deborah Frazier, Jennifer Vermillion. Advanced Cardiac Specialists, Gilbert/Phoenix, AZ
Journal: Journal of the American College of Cardiology (2001)
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies
Authors: Quinto J Gesiotto, David M Swoboda, Najla E. Al Ali, Eric Padron, Andrew T. Kuykendall, Jinming Song, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Rami Komrokji, David A. Sallman
Journal: Blood (2020)
RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY
Authors: Minesh P Mehta, Vinai Gondi, Manmeet Ahluwalia, Paul D Brown
Journal: Neuro-Oncology (2018)

Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality comprising low intensity alternating electric fields. TTFields has demonstrated efficacy in non-small cell lung cancer (NSCLC) in in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma. This prospective, multicenter study [NCT02831959] investigated the efficacy, safety and neurocognitive outcomes of TTFields in NSCLC patients with brain metastases (BMs). NSCLC patients (N=270) with 1–10 BMs are randomized 1:1 to stereotactic radio surgery (SRS) followed by continuous TTFields ((150 kHz, > 18 hours/day) within 7 days of SRS or supportive care. The TTFields portable device delivers TTFields to the brain using 4 transducer arrays and allows normal daily activities. Patients receive the best standard-of-care for their systemic disease. Patients are followed every two months until second intracranial progression. Patients in the control arm could cross over to TTFields at the time of second intracranial progression. Key inclusion criteria: KPS 70, new diagnosis of 1 inoperable or 210 supra- and/or infratentorial BMs from NSCLC amenable to SRS; KPS 70; and optimal therapy for extracranial disease. Prior WBRT or surgical resection of metastases, a single resectable lesion or recurrent BMs were exclusionary. Primary endpoint was time to 1st intracranial progression. Secondary endpoints included time to neurocognitive failure (HVLT, COWAT and TMT), overall survival, radiological response rate (RANO-BM and RECIST V1.1); quality-of-life; adverse events; time to first/second intracranial progression for patients with 14 and 510 BMs; bi-monthly intracranial progression rate from 212 months; and time to second intracranial and distant progression. The sample size (N=270) was calculated using a log-rank test (Lakatos 1988 and 2002) with 80% power at a two sided alpha of 0.05 to detect a hazard ratio of 0.57.
Berlin Letter.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ancient-Modern Concordance in Ayurvedic Plants: Some Examples
Authors: Sukh Dev
Journal: Environmental Health Perspectives (1999)

Ayurveda is the ancient (before 2500 b.c.) Indian system of health care and longevity. It involves a holistic view of man, his health, and illness. Ayurvedic treatment of a disease consists of salubrious use of drugs, diets, and certain practices. Medicinal preparations are invariably complex mixtures, based mostly on plant products. Around 1,250 plants are currently used in various Ayurvedic preparations. Many Indian medicinal plants have come under scientific scrutiny since the middle of the nineteenth century, although in a sporadic fashion. The first significant contribution from Ayurvedic materia medica came with the isolation of the hypertensive alkaloid from the sarpagandha plant (Rouwolfia serpentina), valued in Ayurveda for the treatment of hypertension, insomnia, and insanity. This was the first important ancient-modern concordance in Ayurvedic plants. With the gradual coming of age of chemistry and biology, disciplines central to the study of biologic activities of natural products, many Ayurvedic plants have been reinvestigated. Our work on Commiphora wightti gum-resin, valued in Ayurveda for correcting lipid disorders, has been described in some detail; based on these investigations, a modern antihyperlipoproteinemic drug is on the market in India and some other countries. There has also been concordance for a few other Ayurvedic crude drugs such as Asparagus racemosus, Cedrus deodara, and Psoralea corylifolia.